 | Up a level |
Mc Laughlin, Anna M; Hess, Dagmar; Michelet, Robin; Colombo, Ilaria; Haefliger, Simon; Bastian, Sara; Rabaglio, Manuela; Schwitter, Michael; Fischer, Stefanie; Eckhardt, Katrin; Hayoz, Stefanie; Kopp, Christoph; Klose, Marian; Sessa, Cristiana; Stathis, Anastasios; Halbherr, Stefan; Huisinga, Wilhelm; Joerger, Markus; Kloft, Charlotte (2024). Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer chemotherapy and pharmacology, 94(3), pp. 349-360. Springer 10.1007/s00280-024-04679-z
Ambrodji, Alisa; Sadlon, Angélique; Amstutz, Ursula; Hoch, Dennis; Berger, Martin D.; Bastian, Sara; Offer, Steven M; Largiadèr, Carlo R. (2024). Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD). International journal of molecular sciences, 25(14) MDPI 10.3390/ijms25147599
Colombo, Ilaria; Koster, Kira-Lee; Holer, Lisa; Haefliger, Simon; Rabaglio, Manuela; Bastian, Sara; Schwitter, Michael; Eckhardt, Katrin; Hayoz, Stefanie; Mc Laughlin, Anna M; Kloft, Charlotte; Klose, Marian; Halbherr, Stefan; Baumgartner, Christian; Sessa, Cristiana; Stathis, Anastasios; Hess, Dagmar; Joerger, Markus (2024). TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16). European journal of cancer, 201(113588), p. 113588. Elsevier 10.1016/j.ejca.2024.113588
Mark, Michael; Froesch, Patrizia; Gysel, Katrin; Rothschild, Sacha I; Addeo, Alfredo; Ackermann, Christoph J; Chiquet, Sabrina; Schneider, Martina; Ribi, Karin; Maranta, Angela Fischer; Bastian, Sara; von Moos, Roger; Joerger, Markus; Früh, Martin (2024). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. European journal of cancer, 200(113600), p. 113600. Elsevier 10.1016/j.ejca.2024.113600
Schmulenson, Eduard; Bovet, Cédric; Theurillat, Regula; Decosterd, Laurent Arthur; Largiadèr, Carlo R; Prost, Jean-Christophe; Csajka, Chantal; Bärtschi, Daniela; Guckenberger, Matthias; von Moos, Roger; Bastian, Sara; Joerger, Markus; Jaehde, Ulrich (2022). Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). British journal of clinical pharmacology, 88(12), pp. 5336-5347. Wiley-Blackwell 10.1111/bcp.15461
Gerger, Armin; Eisterer, Wolfgang; Fuxius, Stefan; Bastian, Sara; Koeberle, Dieter; Welslau, Manfred; Akhoundova Sanoyan, Dilara; Maas, Christian; Uhlig, Jens; Fenchel, Klaus; Greil, Richard; von der Heyde, Eyck; Rhyner Agocs, Gaëlle; Weide, Rudolf; Schwager, Monika; Reichenbach, Frank; Modest, Dominik Paul; Fritsch, Ralph (2022). Retrospective Analysis of Treatment Pathways in Patients With BRAFV600E-mutant Metastatic Colorectal Carcinoma - MORSECRC. Anticancer research, 42(10), pp. 4773-4785. International Inst. of Anticancer Research 10.21873/anticanres.15982
Kienle, Dirk L.; Dietrich, Daniel; Ribi, Karin; Wicki, Andreas; Quagliata, Luca; Winterhalder, Ralph C.; Koeberle, Dieter; Horber, Daniel; Bastian, Sara; Kueng, Marc; Saletti, Piercarlo; Helbling, Daniel; Baertschi, Daniela; Lugli, Alessandro; Bernhard, Jürg; Andrieu, Christiane; von Moos, Roger (2019). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of geriatric oncology, 10(2), pp. 304-310. Elsevier 10.1016/j.jgo.2018.11.011
